Follow

Submissions from 2016

Link

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study, J. T. Merrill, R. F. van Vollenhoven, J. P. Buyon, R. A. Furie, W. Stohl, M. Morgan-Cox, C. Dickson, P. W. Anderson, C. Lee, T. Dorner, and +1 additional author

Submissions from 2015

Link

Methods for reducing sepsis mortality in emergency departments and inpatient units, M. E. Doerfler, J. D'Angelo, D. Jacobsen, M. P. Jarrett, A. I. Kabcenell, K. D. Masick, D. Parmentier, K. L. Nelson, and L. Stier

Link

Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis, R. Furie, K. Toder, and E. Zapantis

Link

Treatment Algorithms in Systemic Lupus Erythematosus, C. Muangchan, R. F. van Vollenhoven, S. R. Bernatsky, C. D. Smith, M. Hudson, M. Inanc, N. F. Rothfield, P. T. Nash, R. A. Furie, J. E. Pope, and +4 additional authors

Link

Reply to: Hydroxychloroquine treatment in SLE, J. E. Pope, N. F. Rothfield, R. Ramsey-Goldman, C. D. Smith, S. R. Bernatsky, R. A. Furie, M. Hudson, R. Burgos-Vargas, J. L. Senecal, C. Muangchan, and +4 additional authors

Link

Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study, D. J. Wallace, K. Hobbs, M. E. Clowse, M. Petri, V. Strand, M. Pike, J. T. Merrill, P. Leszczynski, R. Furie, C. Gordon, and +9 additional authors

Submissions from 2014

PDF

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials, R. Furie, M. A. Petri, V. Strand, D. D. Gladman, Z. J. Zhong, and W. W. Freimuth

Link

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus, E. M. Ginzler, D. J. Wallace, J. T. Merrill, R. A. Furie, W. Stohl, W. W. Chatham, A. Weinstein, J. D. McKay, W. J. McCune, M. A. Petri, and +2 additional authors

PDF

A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort, R. L. Gross, J. S. Schwartzman-Morris, M. Krathen, G. Reed, H. Chang, K. C. Saunders, M. C. Fisher, J. D. Greenberg, C. Putterman, A. Broder, and +3 additional authors

PDF

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements, C. Putterman, R. Furie, R. Ramsey-Goldman, A. Askanase, J. Buyon, K. Kalunian, W. W. Chatham, E. Massarotti, K. Kirou, T. Dervieux, and +10 additional authors